Eisler Capital (UK)’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
$133M Buy
674,863
+196,325
+41% +$36.6M 0.61% 35
2024
Q2
$82.1M Buy
478,538
+130,568
+38% +$21.6M 0.53% 47
2024
Q1
$63.4M Buy
347,970
+41,867
+14% +$7.22M 0.53% 41
2023
Q4
$47.4M Buy
306,103
+230,119
+303% +$33.5M 0.37% 60
2023
Q3
$11.3M Buy
+75,984
New +$11.2M 0.07% 205
2022
Q2
Sell
-84,100
Closed -$13.6M 392
2022
Q1
$13.6M Hold
84,100
0.23% 108
2021
Q4
$11.4M Buy
+84,100
New +$9.93M 0.57% 42

Other funds holding ABBV

Eisler Capital (UK)'s ABBV Position: Q3 2024 in Review

Eisler Capital (UK) sold out of AbbVie (ABBV) in Q3 2024, closing a stake of 8,227 shares — an estimated $1.54M sold.

Eisler Capital (UK) first reported a position in ABBV in Q4 2021 and held it in 5 quarters. The position peaked at $4.33M in Q4 2023. 3,498 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.

  • Eisler Capital (UK) reported no remaining AbbVie position as of Q3 2024 after selling out during the quarter.
  • Eisler Capital (UK) sold 8,227 AbbVie shares in Q3 2024, an estimated $1.54M.
  • Eisler Capital (UK) first reported a position in AbbVie in Q4 2021 and held it in 5 quarters.
  • Eisler Capital (UK)'s AbbVie position peaked at $4.33M in Q4 2023.
  • 3,498 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.

Based on Eisler Capital (UK)'s 13F filing for Q3 2024, filed 14 Nov 2024.